.png)
EvoEnzyme is a spin-off from the CSIC dedicated to the Directed Evolution of Enzymes, a disruptive technology for generating new biocatalysts with improved traits. EvoEnzyme cumulates more than 20 years of research of Prof. Miguel Alcalde from CSIC.
EvoEnzyme´s vision is aligned with circular economy and UN SDGs. The company markets evolved enzymes and develops ad-hoc projects for biocatalyst engineering in Pharmaceutical and Industrial sectors, offering a sustainable alternative (“green chemistry”) to non-environmentally friendly processes, e.g. synthesis of fine chemicals, human drug metabolite production, or optimization in drug discovery.
These processes are often accomplished through strategies with several complex steps, pollutants, or high energy consumption. The directed evolution platform of EvoEnzyme, in combination with its computational tools, can design customized biocatalysts to perfectly match process specifications (temperature, pH, substrate specificity) to make the procedure cost-effective, “green” and competitive.
Enzymes play central and all-around role in healthcare. Enzyme-based disease diagnosis and pharmacological drug synthesis are well adopted nowadays. Furthermore, enzyme-based therapies for existing as well as “incurable” diseases are emerging.
EvoEnzyme´s value proposition for healthcare and biopharmaceutical R&D spans throughout different areas of application:
- Biocatalysis of chemical reactions for the synthesis of pharmacological compounds.
- Drug metabolism to assess ADMET of new chemical entities along R&D pipeline.
- Therapeutics by replacement with customised enzymes overcoming deficiencies in native enzymes underlying pathologies.
- Research tools for analytics and diagnostics.
- Biodevices using enzymes as sensors or fuel cells.